Albumin Excipient Market Report 2026

The albumin excipient market size has grown strongly in recent years. It will grow from $5.15 billion in 2025 to $5.47 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising demand for biologics, increasing research in protein-based excipients, growth in pharmaceutical manufacturing, adoption of recombinant albumin, development of stabilized formulations.

The albumin excipient market size is expected to see strong growth in the next few years. It will grow to $7.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to expansion of biopharmaceutical sector, technological advancements in protein excipients, rising prevalence of chronic diseases, growth in contract manufacturing, increasing regulatory approvals for novel drug formulations. Major trends in the forecast period include protein stabilization innovations, excipient formulation advancements, enhanced drug delivery systems, regulatory compliance and gmp adoption, supply chain optimization.

The growing prevalence of chronic diseases is anticipated to fuel the expansion of the albumin excipient market in the coming years. A chronic disease is defined as a condition that persists for three months or longer and may worsen progressively over time. Albumin is widely used as a blood volume expander and represents the most abundant protein circulating in human plasma. It functions as a flexible protein carrier for targeted drug delivery and for enhancing the pharmacokinetic properties of peptide- or protein-based therapeutics, playing a role in the treatment of several conditions, including cancer and diabetes. For example, in February 2024, the World Health Organization, a United Nations agency based in Switzerland, projected that more than 35 million new cancer cases will occur by 2050, reflecting a 77% increase compared to the estimated 20 million cases reported in 2022. Consequently, the increasing burden of chronic diseases is contributing to the growth of the albumin excipient market.

Key companies operating in the albumin excipient market are increasingly embracing strategic partnerships to support the biotechnology and pharmaceutical industries. Strategic partnerships involve collaboration between companies to combine resources, expertise, and capabilities in order to achieve shared objectives and long-term success. For instance, in October 2023, ARTES Biotechnology GmbH, a Germany-based biotechnology company, partnered with Basic Pharma, a Netherlands-based pharmaceutical company, to advance recombinant protein manufacturing. Through this collaboration, the companies seek to enhance pharmaceutical recombinant protein production by optimizing the supply chain and shortening the time required to bring new products to market.

In November 2025, Evonik, a Germany-based specialty chemicals company, entered into a partnership with InVitria to broaden access to animal-free human serum albumin for biopharmaceutical innovation. Through this collaboration, Evonik aims to reinforce its Precision Biosolutions portfolio by delivering safer and more consistent albumin excipients that enable improved manufacturing efficiency and greater product stability. InVitria is a US-based biopharmaceutical company focused on the development and production of recombinant human serum albumin excipients.

Major companies operating in the albumin excipient market are Albumin Therapeutics LLC, Biotest AG, CSL Behring, Grifols S.A., InVitria Inc., Octapharma AG, Kedrion Biopharma, LFB USA Inc., Baxter International Inc., Merck KGaA, Albumedix A/S, Bio Products Laboratory Ltd., Ventria Bioscience Inc., Novartis AG, China Biologic Products Holdings Inc., ProMetic Life Sciences Inc., Sanquin, Takeda Pharmaceutical Company Limited, FUJIFILM Irvine Scientific Inc., Shire Plc, Biopharma, Hualan Biological Engineering Inc., Shanghai RAAS Blood Products Co. Ltd.

North America was the largest region in the Albumin Excipient market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global albumin excipient market report during the forecast period. The regions covered in the albumin excipient market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the albumin excipient market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the albumin excipient market by affecting the import and export costs of raw materials and specialized proteins required for formulation. Rising tariffs have increased production expenses for segments like recombinant albumin and human serum albumin, particularly in North America and Europe. Pharmaceutical and biotechnology industries reliant on imported excipients face supply chain disruptions, while some local manufacturers benefit from reduced competition. Overall, tariffs have encouraged diversification of sourcing and adoption of locally produced albumin excipients.

The albumin excipient market research report is one of a series of new reports that provides albumin excipient market statistics, including albumin excipient industry global market size, regional shares, competitors with a albumin excipient market share, detailed albumin excipient market segments, market trends and opportunities, and any further data you may need to thrive in the albumin excipient industry. This albumin excipient market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Albumin excipient is a protein commonly found in blood. An excipient is an inactive substance that functions as a carrier or stabilizing agent for the active pharmaceutical ingredient.

The primary product types of albumin excipients include human serum albumin and recombinant albumin. Human serum albumin is the main protein produced by the liver and is naturally present in human plasma. These excipients are utilized by a range of end users, including the pharmaceutical and biotechnology industry, research institutes, and others.

The albumin excipient market consists of sales of ovalbumin, and bovine serum albumin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.